JP2025516381A5 - - Google Patents
Info
- Publication number
- JP2025516381A5 JP2025516381A5 JP2024566849A JP2024566849A JP2025516381A5 JP 2025516381 A5 JP2025516381 A5 JP 2025516381A5 JP 2024566849 A JP2024566849 A JP 2024566849A JP 2024566849 A JP2024566849 A JP 2024566849A JP 2025516381 A5 JP2025516381 A5 JP 2025516381A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ligand
- drug conjugate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210515898.0 | 2022-05-12 | ||
| CN202210515898 | 2022-05-12 | ||
| CN202210999585.7 | 2022-08-19 | ||
| CN202210999585 | 2022-08-19 | ||
| CN202310406469.4 | 2023-04-14 | ||
| CN202310406469 | 2023-04-14 | ||
| PCT/CN2023/093503 WO2023217227A1 (zh) | 2022-05-12 | 2023-05-11 | 喜树碱类衍生物及配体-药物偶联物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516381A JP2025516381A (ja) | 2025-05-27 |
| JP2025516381A5 true JP2025516381A5 (enExample) | 2026-05-13 |
Family
ID=88729758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566849A Pending JP2025516381A (ja) | 2022-05-12 | 2023-05-11 | カンプトテシン系誘導体及びリガンド－薬物複合体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250304717A1 (enExample) |
| EP (1) | EP4523704A1 (enExample) |
| JP (1) | JP2025516381A (enExample) |
| KR (1) | KR20250044188A (enExample) |
| CN (1) | CN119136840B (enExample) |
| AU (1) | AU2023266865A1 (enExample) |
| TW (1) | TW202408586A (enExample) |
| WO (1) | WO2023217227A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| CN120858098A (zh) * | 2023-05-04 | 2025-10-28 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2025130905A1 (zh) | 2023-12-18 | 2025-06-26 | 山东先声生物制药有限公司 | 抗FGFR2b抗体-药物缀合物及其应用 |
| WO2025146137A1 (zh) * | 2024-01-05 | 2025-07-10 | 海南先声再明医药股份有限公司 | 抗liv-1抗体药物偶联物及其用途 |
| TW202613172A (zh) * | 2024-05-31 | 2026-04-01 | 大陸商江蘇先聲生物製藥有限公司 | 抗cdh17抗體、綴合物及其應用 |
| WO2025247330A1 (zh) * | 2024-05-31 | 2025-12-04 | 江苏先声生物制药有限公司 | 抗EGFR×cMet双特异性抗体的药物偶联物及其用途 |
| WO2026082031A1 (zh) * | 2024-10-14 | 2026-04-23 | 先声再明医药股份有限公司 | 一种包含抗cdh6抗体或其adc的药物组合物 |
| WO2026120507A1 (en) | 2024-12-04 | 2026-06-11 | Daiichi Sankyo Company, Limited | An antibody-drug conjugate for use in the treatment of drug-resistant cancer |
| WO2026130368A1 (zh) * | 2024-12-19 | 2026-06-25 | 映恩生物制药（苏州）有限公司 | 一种药物偶联物中间体及其制备方法 |
| WO2026142983A1 (en) * | 2024-12-23 | 2026-07-02 | Bristol-Myers Squibb Company | Liv1-tlr7/8 immunomodulatory conjugate and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PT3156420T (pt) | 2010-12-06 | 2019-05-27 | Seattle Genetics Inc | Anticorpos humanizados a liv-1 e seu uso para tratar o cancro |
| TWI926682B (zh) | 2017-05-15 | 2026-05-21 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| CN111936169A (zh) | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| UA130338C2 (uk) | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| EP3636284A1 (en) | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| MX2021011494A (es) | 2019-03-26 | 2021-12-15 | Univ California | Células t modificadas con el receptor de antígeno quimérico (t car) para el tratamiento de cánceres hematológicos y tumores sólidos. |
| RS64961B1 (sr) | 2019-04-26 | 2024-01-31 | Immunogen Inc | Derivati kamptotecina |
| KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| BR112022005114A2 (pt) * | 2019-10-04 | 2022-06-21 | Seagen Inc | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco |
| WO2021067820A1 (en) * | 2019-10-04 | 2021-04-08 | Seagen Inc. | Formulation of antibody-drug conjugate |
| KR20220079606A (ko) * | 2019-10-04 | 2022-06-13 | 씨젠 인크. | 캄프토테신 펩티드 접합체 |
-
2023
- 2023-05-11 WO PCT/CN2023/093503 patent/WO2023217227A1/zh not_active Ceased
- 2023-05-11 AU AU2023266865A patent/AU2023266865A1/en active Pending
- 2023-05-11 EP EP23802996.1A patent/EP4523704A1/en active Pending
- 2023-05-11 US US18/864,884 patent/US20250304717A1/en active Pending
- 2023-05-11 KR KR1020247041224A patent/KR20250044188A/ko active Pending
- 2023-05-11 TW TW112117605A patent/TW202408586A/zh unknown
- 2023-05-11 CN CN202380037219.6A patent/CN119136840B/zh active Active
- 2023-05-11 JP JP2024566849A patent/JP2025516381A/ja active Pending